Sarepta Therapeutics announced a major restructuring, cutting approximately 36% of its workforce—about 500 jobs—following the deaths of two Duchenne muscular dystrophy (DMD) patients treated with its gene therapy Elevidys. Both patients succumbed to acute liver failure, prompting the company to suspend Elevidys administration in non-ambulatory patients and the FDA to request a black box warning for liver injury. Sarepta is shifting its R&D focus toward siRNA therapies for rare genetic diseases while pausing several gene therapy programs. The company is also proposing enhanced immunosuppressive regimens and conducting new clinical studies to manage liver toxicity.